Tag: bipolar disorder
An Open-Label Prophylaxis Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) Combination for Rapid Cycling Bipolar Disorder
by Sriram Ramaswamy, MD; David Driscoll, PhD; and Lynette M. Smith, PhD Dr. Ramaswamy is with the Department of Psychiatry, Creighton University School of Medicine, Omaha, Nebraska, and the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Driscoll is with the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Smith is with the […]
MicroRNAs as Biomarkers for Psychiatric Conditions: A Review of Current Research
by Anoop Narahari, MD; Mariyah Hussain, MD; and Venkatesh Sreeram, MD Drs. Narahari, Hussain, and Sreeram are from the University of Alabama, Department of Psychiatry and Behavioral sciences, Birmingham, Alabama. Innov Clin Neurosci. 2017;14(1–2):53–55
Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases
by Joanna P. MacEwan, PhD; Seth Seabury, PhD; Myrlene Sanon Aigbogun, MPH; Siddhesh Kamat, MS, MBA; Emma van Eijndhoven, MS, MA; Clement Francois, PhD; Crystal Henderson, PharmD, BCPP; and Leslie Citrome, MD, MPH Dr. MacEwan and Ms. van Eijndhoven are with Precision Health Economics in Los Angeles, California, USA; Dr. Seabury is with the University […]
Letter to the Editor: Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use Disorders
Innov Clin Neurosci. 2016;13(7–8):13–14
The Neuroscience Report—Vol. 33 (January 11, 2016): Bipolar Disorder
The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks. Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information. This week’s topic: Bipolar […]
Letter to the Editor: Comparing Injection Site Pain with Paliperidone Palmitate Versus First-generation Depot Antipsychotics in Subjects with Schizophrenia
Dear Editor: Atypical long-acting injectable (LAI) antipsychotics may improve treatment options for patients with serious mental illnesses, such as schizophrenia and bipolar disorder.[1] A systematic review of 1,700 outpatients from 10 different studies reported a 30-percent decrease in the relative risk for relapse with LAIs versus oral antipsychotic medications.[2] However, first-generation depot medications, such as […]
Lurasidone: A New Treatment Option for Bipolar Depression— A Review
by Radhika Bawa, MD, and Jonathan R. Scarff, MD Dr. Bawa is with Lehman College, the City University of New York, Bronx, New York; and Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina. Innov Clin Neurosci. 2015;12(1–2):21–23
Systematic Study of Structured Diagnostic Procedures in Outpatient Psychiatric Rehabilitation: A Three-year, Three-cohort Study of the Stability of Psychiatric Diagnoses
by Raymond Kotwicki, MD, and Philip D. Harvey, PhD Dr. Kotwicki is with Skyland Trail and Emory University in Atlanta, Georgia; and Dr. Harvey is with the University of Miami Miller School of Medicine, Miami, Florida. Innov Clin Neurosci. 2013;10(5–6):14–19
Adjunctive Methylphenidate in the Treatment of Bulimia Nervosa Co-occurring with Bipolar Disorder and Substance Dependence
by Anna I. Guerdjikova, PhD, and Susan L. McElroy, MD Dr. Guerdjikova is from the Lindner Center of HOPE in Mason, Ohio, and Dr. McElroy is from the Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine in Cincinnati, Ohio. Innov Clin Neurosci. 2013;10(2):30–33
